# Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

> **NCT00666835** · PHASE3 · COMPLETED · sponsor: **Sandoz** · enrollment: 478 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** HX575 epoetin alfa Hexal AG
- **DRUG:** ERYPO®, Janssen-Cilag

## Key facts

- **NCT ID:** NCT00666835
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00666835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00666835, "Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00666835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*